Clinical risk scoring for predicting non‐alcoholic fatty liver disease in metabolic syndrome patients (NAFLD‐MS score)

摘要

Abstract Background & Aims Non‐alcoholic fatty liver disease ( NAFLD ) can progress from simple steatosis to hepatocellular carcinoma. None of tools have been developed specifically for high‐risk patients. This study aimed to develop a simple risk scoring to predict NAFLD in patients with metabolic syndrome (MetS). Methods A total of 509 patients with MetS were recruited. All were diagnosed by clinicians with ultrasonography‐confirmed whether they were patients with NAFLD . Patients were randomly divided into derivation (n=400) and validation (n=109) cohort. To develop the risk score, clinical risk indicators measured at the time of recruitment were built by logistic regression. Regression coefficients were transformed into item scores and added up to a total score. A risk scoring scheme was developed from clinical predictors: BMI ≥25, AST/ALT ≥1, ALT ≥40, type 2 diabetes mellitus and central obesity. The scoring scheme was applied in validation cohort to test the performance. Results The scheme explained, by area under the receiver operating characteristic curve (AuROC), 76.8% of being NAFLD with good calibration (Hosmer‐Lemeshow χ 2 =4.35; P =.629). The positive likelihood ratio of NAFLD in patients with low risk (scores below 3) and high risk (scores 5 and over) were 2.32 (95% CI: 1.90‐2.82) and 7.77 (95% CI: 2.47‐24.47) respectively. When applied in validation cohort, the score showed good performance with Au ROC 76.7%, and illustrated 84%, and 100% certainty in low‐ and high‐risk groups respectively. Conclusions A simple and non‐invasive scoring scheme of five predictors provides good prediction indices for NAFLD in MetS patients. This scheme may help clinicians in order to take further appropriate action.